Related medicinesDesmopressinTerlipressinVasopressinTolvaptan
Where it comes from
- Made in
- Large neurons of the supraoptic and paraventricular nuclei, whose axons end in the posterior pituitary
- Sent out by
- A rise in blood osmolality of one percent, a fall in blood volume or pressure, nausea, pain and stress
- Acts on
- Collecting ducts of the kidney (water channels)
- Arterioles
- Pituitary corticotrophs (ACTH)
- Liver (glycogen)
- Brain circuits of social behaviour
What it does
- Puts aquaporin-2 water channels into the collecting duct so water is kept and urine concentrates
- Constricts vessels in shock, when it is released in huge amounts
- Governs pair bonding and aggression in voles, and social behaviour in people in a subtler way
In medicine
- Desmopressin, a V2-selective analogue, treats arginine vasopressin deficiency (central diabetes insipidus), bedwetting, and bleeding in haemophilia A and von Willebrand disease
- Vasopressin infusion is a second-line pressor in septic shock; terlipressin treats hepatorenal syndrome and variceal bleeding 1
- Tolvaptan, a V2 blocker, treats low sodium from inappropriate vasopressin and slows polycystic kidney disease 2
Beyond the body’s own use
- In 778 patients with septic shock, adding vasopressin to noradrenaline did not lower mortality overall, which is why it stays a second-line rather than a first-line pressor 1
- Tolvaptan slowed cyst growth and the loss of kidney function over three years in 1,445 patients with polycystic kidney disease, at the cost of thirst and raised liver enzymes 2
- Intranasal vasopressin improved social abilities against placebo in a pilot trial of 30 children with autism, a result that has not been repeated at scale 3
- Blocking the same system was tried too: balovaptan, a V1a blocker, improved adaptive behaviour in a phase 2 trial in men with autism, and the later trials did not confirm it 4
Sources
- Russell et al., Vasopressin versus norepinephrine infusion in patients with septic shock, New England Journal of Medicine 2008
- Torres et al., Tolvaptan in patients with autosomal dominant polycystic kidney disease, New England Journal of Medicine 2012
- Parker et al., Intranasal vasopressin improves social deficits in children with autism, Science Translational Medicine 2019
- Bolognani et al., A vasopressin V1a receptor antagonist in men with autism spectrum disorder, Science Translational Medicine 2019
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.